Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunphenon EGCG in early-stage Alzheimer's disease
2009-009656-20Phase 2Terminated
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Mar 2009
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of Sunphenon EGCG in Alzheimer's disease (AD), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: ADAS-Cog change from baseline to 18 months. Started Mar 2009; status: terminated.
02
Drugs
Sunphenon EGCG
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2009-009656-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-009656-20.